PropThink: Ziopharm Offers a Positive Risk/Reward Profile

[ACN Newswire] – By David SobekPalifosfamide is a bifunctional alkylator developed by Ziopharm Oncology (NASDAQ:ZIOP) for the treatment of a number of cancers. Soft tissue sarcoma (STS) is the most advanced program with … more

View todays social media effects on ZIOP

View the latest stocks trending across Twitter. Click to view dashboard